학술논문

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma.
Document Type
Article
Source
Cancers. Apr2020, Vol. 12 Issue 4, p924-924. 1p.
Subject
*ANTINEOPLASTIC agents
*CELLULAR signal transduction
*IMMUNOTHERAPY
*MONOCLONAL gammopathies
*MULTIPLE myeloma
*PROTEINS
*PROGRAMMED cell death 1 receptors
Language
ISSN
2072-6694
Abstract
PD-L1 expressed on tumor cells contributes to disease progression with evasion from tumor immunity. Plasma cells from multiple myeloma (MM) patients expressed higher levels of PD-L1 compared with healthy volunteers and monoclonal gammopathy of undetermined significance (MGUS) patients, and its expression is significantly upregulated in relapsed/refractory patients. Furthermore, high PD-L1 expression is induced by the myeloma microenvironment and PD-L1+ patients with MGUS and asymptomatic MM tend to show disease progression. PD-L1 expression on myeloma cells was associated with more proliferative potential and resistance to antimyeloma agents because of activation of the Akt pathway through PD-1-bound PD-L1 in MM cells. Those data suggest that PD-L1 plays a crucial role in the disease progression of MM. [ABSTRACT FROM AUTHOR]